Marksans Pharma Q2 FY27: revenue up 30.5% to ₹940 Cr, net profit up 44.8% to ₹144 Cr
Results · Finvezto · 4 Nov 2026 · Marksans Pharma (MARKSANS)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 940 | +11.8% | +30.5% |
| Operating profit | 214 | +0.6% | +48.3% |
| Net profit | 144 | -10.0% | +44.8% |
| Operating margin | 22.8% | -2.5 pp | +2.7 pp |
| Net margin | 15.3% | -3.7 pp | +1.5 pp |
Key points
- Marksans Pharma reported operating revenue of Rs 940.2 crore for Q2 FY27, up 30.5% YoY, with EBITDA rising 48.3% to Rs 214.3 crore and PAT increasing 44.8% to Rs 143.5 crore. NSE filing
- Growth was led by the UK and Europe formulation business surging 64.9% YoY to Rs 404.6 crore, while H1 FY27 net cash from operating activities reached Rs 322 crore. NSE filing
- Revenue was ₹940 Cr, up 30.5% on a year earlier and up 11.8% on the quarter before. Finvezto data
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 21.3%, 22.8%, 25.3%, 22.8%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 114, 149, 159, 144.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.